What's new — Hypertension¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 3 |
| last 3 months | 8 |
| last 6 months | 20 |
| last year | 55 |
| older than a year | 713 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-08-02 | Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial — Circulation ([PMID 42666029](https://pubmed.ncbi.nlm.nih.gov/42666029/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-08-02 | Baxdrostat: First Approval — Drugs ([PMID 42625106](https://pubmed.ncbi.nlm.nih.gov/42625106/){target="_blank" rel="noopener"}) | pharmacological-therapy, resistant-and-refractory-hypertension |
| 2026-08-01 | Prevalence of adherence to antihypertensive treatment: a comparison of drug biochemical analysis and the self-report scale — Clin Hypertens ([PMID 42564271](https://pubmed.ncbi.nlm.nih.gov/42564271/){target="_blank" rel="noopener"}) | adherence-and-implementation |
| 2026-07-03 | Association of a CCB-Related Pharmacogenomics-Guided Strategy with Blood Pressure Outcomes and Short-Term Safety in Chinese Patients with Hypertension: A Secondary Exploratory Analysis of Two Randomized Cohorts — Drug Healthc Patient Saf ([PMID 42553612](https://pubmed.ncbi.nlm.nih.gov/42553612/){target="_blank" rel="noopener"}) | genetics-and-monogenic-forms |
| 2026-07-01 | Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study — Eur J Neurol ([PMID 42397158](https://pubmed.ncbi.nlm.nih.gov/42397158/){target="_blank" rel="noopener"}) | hypertensive-emergencies |
| 2026-07-01 | Innovative Device-Based Treatments for Hypertension — Am J Hypertens ([PMID 41344842](https://pubmed.ncbi.nlm.nih.gov/41344842/){target="_blank" rel="noopener"}) | device-and-interventional-therapy |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — J Am Coll Cardiol ([PMID 42265997](https://pubmed.ncbi.nlm.nih.gov/42265997/){target="_blank" rel="noopener"}) | lifestyle-and-dietary-management, special-populations |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 42263157](https://pubmed.ncbi.nlm.nih.gov/42263157/){target="_blank" rel="noopener"}) | special-populations |
| 2026-06-03 | Terminal Digit Preference and Threshold Avoidance in Digital Blood Pressure Measurements During Pregnancy: Secondary Analysis of Data From the CLIP and PRECISE Cohorts — JMIR Mhealth Uhealth ([PMID 42234864](https://pubmed.ncbi.nlm.nih.gov/42234864/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-06-01 | Polygenic risk score translation across diverse populations — Front Cardiovasc Med ([PMID 42395874](https://pubmed.ncbi.nlm.nih.gov/42395874/){target="_blank" rel="noopener"}) | genetics-and-monogenic-forms, special-populations |
| 2026-05-15 | Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program — EuroIntervention ([PMID 42137915](https://pubmed.ncbi.nlm.nih.gov/42137915/){target="_blank" rel="noopener"}) | device-and-interventional-therapy |
| 2026-05-15 | Effect of intensive blood pressure control in patients with resistant hypertension: insights from the STEP trial — Eur J Prev Cardiol ([PMID 40796327](https://pubmed.ncbi.nlm.nih.gov/40796327/){target="_blank" rel="noopener"}) | resistant-and-refractory-hypertension |
| 2026-05-02 | Endogenous and exogenous determinants of sex differences in blood pressure — NPJ Cardiovasc Health ([PMID 42185679](https://pubmed.ncbi.nlm.nih.gov/42185679/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-05-01 | Managing Blood Pressure Beyond Viral Suppression for Patient and Provider Perspectives on Antihypertensive Medication Adherence in HIV Care: A Qualitative Study — Res Sq ([PMID 42239779](https://pubmed.ncbi.nlm.nih.gov/42239779/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-05-01 | Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial — Lancet HIV ([PMID 42067280](https://pubmed.ncbi.nlm.nih.gov/42067280/){target="_blank" rel="noopener"}) | special-populations |
| 2026-04-28 | Diagnosis and Management of Resistant Hypertension: A Review — JAMA ([PMID 41870448](https://pubmed.ncbi.nlm.nih.gov/41870448/){target="_blank" rel="noopener"}) | clinical-trials-landscape, device-and-interventional-therapy, red-flags-and-safety-concerns, resistant-and-refractory-hypertension |
| 2026-04-22 | Persistent Renin Suppression After Unilateral Adrenalectomy for Primary Aldosteronism: Implications for Adverse Outcome? — J Clin Endocrinol Metab ([PMID 41175007](https://pubmed.ncbi.nlm.nih.gov/41175007/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-04-02 | A Review of Clinical Trial and Meta-Analyses of BP Treatment Strategies for Patients with Orthostatic Hypotension: Blood Pressure Management in Patients with Hypertension and Orthostatic Hypotension — Curr Hypertens Rep ([PMID 42033492](https://pubmed.ncbi.nlm.nih.gov/42033492/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-04-01 | Is It Time to Retire Aldosterone Suppression Testing? — Am J Hypertens ([PMID 40887827](https://pubmed.ncbi.nlm.nih.gov/40887827/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2026-03-07 | Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial — Lancet ([PMID 41794437](https://pubmed.ncbi.nlm.nih.gov/41794437/){target="_blank" rel="noopener"}) | clinical-trials-landscape, pharmacological-therapy, resistant-and-refractory-hypertension |
| 2026-03-03 | Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies — Adv Ther ([PMID 41915114](https://pubmed.ncbi.nlm.nih.gov/41915114/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2026-03-01 | Aldosterone and Impaired Nocturnal Blood Pressure Decline in Primary Aldosteronism — J Am Heart Assoc ([PMID 41804894](https://pubmed.ncbi.nlm.nih.gov/41804894/){target="_blank" rel="noopener"}) | definition-measurement-and-diagnosis |
| 2026-02-26 | (title unavailable) — ** ([PMID 31577399](https://pubmed.ncbi.nlm.nih.gov/31577399/){target="_blank" rel="noopener"}) | guidelines |
| 2026-02-02 | Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT — Hypertension ([PMID 41717679](https://pubmed.ncbi.nlm.nih.gov/41717679/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2026-02-01 | Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention — Am J Obstet Gynecol ([PMID 41707896](https://pubmed.ncbi.nlm.nih.gov/41707896/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2026-02-01 | Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trial — Trials ([PMID 41689048](https://pubmed.ncbi.nlm.nih.gov/41689048/){target="_blank" rel="noopener"}) | clinical-trials-landscape, special-populations |
| 2026-02-01 | Executive Summary of the 2024 Philippine Clinical Practice Guidelines on the Diagnosis and Management of Acute Severe Blood Pressure Elevation — J Clin Hypertens (Greenwich) ([PMID 41614648](https://pubmed.ncbi.nlm.nih.gov/41614648/){target="_blank" rel="noopener"}) | hypertensive-emergencies |
| 2026-01-09 | Blood pressure management in stroke: comparative review of the 2025 AHA/ACC/AANP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM, 2024 ESC, 2023 ESH, and 2025 JSH guidelines — Hypertens Res ([PMID 41514030](https://pubmed.ncbi.nlm.nih.gov/41514030/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-06 | Global trends in hypertension prevalence, awareness, treatment, and control — Curr Opin Nephrol Hypertens ([PMID 41495934](https://pubmed.ncbi.nlm.nih.gov/41495934/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-01-03 | Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project — J Am Heart Assoc ([PMID 41614323](https://pubmed.ncbi.nlm.nih.gov/41614323/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2026-01-01 | Inpatient Admissions for Hypertensive Crises in the USA by Race and Gender: A Retrospective Study From the National Inpatient Sample From 2016 to 2022 — J Clin Hypertens (Greenwich) ([PMID 41543283](https://pubmed.ncbi.nlm.nih.gov/41543283/){target="_blank" rel="noopener"}) | hypertensive-emergencies |
| 2026-01-01 | Screening and Diagnosis of Primary Aldosteronism in Patients Using Renin-Angiotensin System Inhibitors — J Clin Hypertens (Greenwich) ([PMID 41491647](https://pubmed.ncbi.nlm.nih.gov/41491647/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2025-12-19 | Quality of life effects of renal artery stenting versus medical therapy for atherosclerotic renal-artery stenosis: results from the randomized CORAL trial — Eur Heart J Qual Care Clin Outcomes ([PMID 39402005](https://pubmed.ncbi.nlm.nih.gov/39402005/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2025-12-09 | Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension — Hypertension ([PMID 41363010](https://pubmed.ncbi.nlm.nih.gov/41363010/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2025-12-03 | Associations Between Polygenic Risk Score for Blood Pressure and Risk of Hypertension in Northeast Asian Individuals — J Am Heart Assoc ([PMID 41467372](https://pubmed.ncbi.nlm.nih.gov/41467372/){target="_blank" rel="noopener"}) | genetics-and-monogenic-forms |
| 2025-12-02 | Life-Course Blood Pressure Levels, 38-Year Tracking, and Prediction of Hypertension — J Am Heart Assoc ([PMID 41431974](https://pubmed.ncbi.nlm.nih.gov/41431974/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2025-12-01 | Patient Selection for Revascularization of Atherosclerotic Renal Artery Stenosis: Comparing the Importance of Stenosis Severity and Clinical Phenotype — Kidney Med ([PMID 41623301](https://pubmed.ncbi.nlm.nih.gov/41623301/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2025-12-01 | Postpartum management of the hypertensive disorders of pregnancy: a systematic review and meta-analysis — Am J Obstet Gynecol ([PMID 41421750](https://pubmed.ncbi.nlm.nih.gov/41421750/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
| 2025-12-01 | Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial — BMJ Open ([PMID 41419284](https://pubmed.ncbi.nlm.nih.gov/41419284/){target="_blank" rel="noopener"}) | clinical-trials-landscape, secondary-hypertension |
| 2025-12-01 | Pooled randomised QUARTET trials assessing effectiveness of a single pill for hypertension — Open Heart ([PMID 41419232](https://pubmed.ncbi.nlm.nih.gov/41419232/){target="_blank" rel="noopener"}) | pharmacological-therapy |
| 2025-12-01 | Exploring adherence to antihypertensive medication in Black African and Black Caribbean residents in South East London: a qualitative study — BJGP Open ([PMID 40389279](https://pubmed.ncbi.nlm.nih.gov/40389279/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-11-05 | Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension — J Hypertens ([PMID 41195725](https://pubmed.ncbi.nlm.nih.gov/41195725/){target="_blank" rel="noopener"}) | resistant-and-refractory-hypertension |
| 2025-11-02 | Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023 — J Am Coll Cardiol ([PMID 41295934](https://pubmed.ncbi.nlm.nih.gov/41295934/){target="_blank" rel="noopener"}) | adherence-and-implementation, epidemiology-and-burden |
| 2025-11-02 | Intensive Versus Standard Blood Pressure Control in Type 2 Diabetes: Cardiovascular and Microvascular Outcomes — High Blood Press Cardiovasc Prev ([PMID 41266861](https://pubmed.ncbi.nlm.nih.gov/41266861/){target="_blank" rel="noopener"}) | blood-pressure-targets, special-populations |
| 2025-11-01 | Dietary salt intake and cardiovascular outcomes: an umbrella review of meta-analyses and dose-response evidence — Ann Med ([PMID 41243115](https://pubmed.ncbi.nlm.nih.gov/41243115/){target="_blank" rel="noopener"}) | lifestyle-and-dietary-management |
| 2025-10-02 | Atherosclerotic renal artery stenosis in the post-CORAL Trial Era. A narrative review — Curr Probl Cardiol ([PMID 41167516](https://pubmed.ncbi.nlm.nih.gov/41167516/){target="_blank" rel="noopener"}) | secondary-hypertension |
| 2025-10-02 | Adaptive Immune System in Hypertension: Implicating the Role of T Cells — Curr Cardiol Rev ([PMID 41121514](https://pubmed.ncbi.nlm.nih.gov/41121514/){target="_blank" rel="noopener"}) | pathophysiology |
| 2025-10-02 | A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults — Nat Med ([PMID 41039116](https://pubmed.ncbi.nlm.nih.gov/41039116/){target="_blank" rel="noopener"}) | lifestyle-and-dietary-management |
| 2025-10-01 | Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without CKD: A Post Hoc Analysis of SPRINT and ACCORD-BP Trials — J Diabetes ([PMID 41117098](https://pubmed.ncbi.nlm.nih.gov/41117098/){target="_blank" rel="noopener"}) | blood-pressure-targets, special-populations |
| 2025-10-01 | Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial — J Am Coll Cardiol ([PMID 41105077](https://pubmed.ncbi.nlm.nih.gov/41105077/){target="_blank" rel="noopener"}) | blood-pressure-targets, special-populations |
| 2025-10-01 | Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet ([PMID 41092926](https://pubmed.ncbi.nlm.nih.gov/41092926/){target="_blank" rel="noopener"}) | epidemiology-and-burden, overview |
| 2025-10-01 | Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension — J Am Heart Assoc ([PMID 41085208](https://pubmed.ncbi.nlm.nih.gov/41085208/){target="_blank" rel="noopener"}) | definition-measurement-and-diagnosis |
| 2025-10-01 | Diastolic Blood Pressure and Cognitive Function in Adults With Achieved Systolic Blood Pressure Below 130 mm Hg: Insights From the SPRINT-MIND Trial — Circ Cardiovasc Qual Outcomes ([PMID 41070444](https://pubmed.ncbi.nlm.nih.gov/41070444/){target="_blank" rel="noopener"}) | risk-and-outcomes |
| 2025-09-06 | Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial — J Am Soc Nephrol ([PMID 40913594](https://pubmed.ncbi.nlm.nih.gov/40913594/){target="_blank" rel="noopener"}) | clinical-trials-landscape, pharmacological-therapy |
| 2025-09-04 | Impact of Blood Pressure Self-Management on Vascular Remodeling After Hypertensive Pregnancy — Hypertension ([PMID 40905148](https://pubmed.ncbi.nlm.nih.gov/40905148/){target="_blank" rel="noopener"}) | hypertension-in-pregnancy |
Trials — what has moved¶
61 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 9 |
| trial records updated in the last 2 months | 15 |
| trial records updated in the last 3 months | 20 |
| trial records updated in the last 6 months | 27 |
| trial records updated in the last year | 40 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pr | PHASE3 | 218 | Least Square Mean Difference for Change From Baseline in Ambulatory 24 | 2 | 95 | 0 |
| 2026-06-03 | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotr | PHASE2 | 60 | Placebo-adjusted Change From Baseline in Automated Office Blood Pressu | 2 | 47 | 0 |
| 2026-04-30 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Mode | PHASE1, PHASE2 | 36 | Number of Participants With Adverse Events (AEs) | 0 | 16 | 0 |
| 2025-12-17 | A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropi | PHASE2 | 48 | Number of Participants With Serum Total Cortisol Level Before and Afte | 0 | 12 | 0 |
| 2025-07-09 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequa | PHASE2 | 663 | Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assess | 33 | 278 | 2 |
| 2024-12-27 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With | PHASE2 | 394 | Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM | 44 | 342 | 3 |
| 2023-09-15 | SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyra | NA | 337 | Change in Systolic Blood Pressure as Measured by 24-hour Ambulatory Bl | 77 | 244 | 3 |
| 2023-06-28 | A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rH | PHASE2 | 275 | Change From Baseline in Mean Seated Systolic BP (SBP) | 10 | 40 | 0 |
| 2023-03-21 | A Research Study to Show the Effect of Aprocitentan in the Treatment o | PHASE3 | 730 | Change From Baseline to Week 4 of Double-blind Treatment in Mean Troug | 128 | 160 | 11 |
| 2021-05-27 | SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study | NA | 366 | Number of Participants With Major Adverse Events (MAE) Defined as a Co | 74 | 304 | 3 |
| 2020-04-13 | Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With | PHASE2 | 1659 | Change From Baseline to End of Double-blind Treatment in Sitting Diast | 3 | 151 | 0 |
31 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| adherence-and-implementation | 2026-08-02 | 3 | 58 |
| pharmacological-therapy | 2026-08-02 | 8 | 69 |
| resistant-and-refractory-hypertension | 2026-08-02 | 5 | 47 |
| genetics-and-monogenic-forms | 2026-07-03 | 3 | 44 |
| device-and-interventional-therapy | 2026-07-01 | 3 | 48 |
| hypertensive-emergencies | 2026-07-01 | 3 | 37 |
| lifestyle-and-dietary-management | 2026-06-09 | 3 | 52 |
| special-populations | 2026-06-09 | 8 | 80 |
| hypertension-in-pregnancy | 2026-06-03 | 4 | 52 |
| epidemiology-and-burden | 2026-05-02 | 5 | 42 |
| patient-experience-and-advocacy | 2026-05-01 | 2 | 39 |
| clinical-trials-landscape | 2026-04-28 | 5 | 40 |
| red-flags-and-safety-concerns | 2026-04-28 | 2 | 57 |
| secondary-hypertension | 2026-04-22 | 7 | 63 |
| definition-measurement-and-diagnosis | 2026-03-01 | 2 | 72 |
| guidelines | 2026-02-26 | 2 | 51 |
| blood-pressure-targets | 2025-11-02 | 3 | 42 |
| pathophysiology | 2025-10-02 | 1 | 73 |
| overview | 2025-10-01 | 1 | 57 |
| risk-and-outcomes | 2025-10-01 | 1 | 39 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.